Thrombocytopenia as a Clinical Manifestation of Hepatitis C Among Patients With a Positive Anti-HCV Test

Bano, Safia; Qureshi, Javeria S.; Raza, Afsheen; Hashmi, Khalid Zafar

doi:10.17795/iji-35094

Cited by 10 publications

(9 citation statements)

References 17 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most common abnormalities reported in patients with CHC is thrombocytopenia or low platelet count and the most commonly known causes include impaired production of platelets, increased platelet destruction or consumption, frequent bleeding, and infectious diseases, such as viral infection . Several studies reported that CHC infection is strongly correlated with thrombocytopenia, indicating that 64–76% of CHC infections, fibrosis, and cirrhosis showed manifestations of thrombocytopenia, compared with 6% of non‐cirrhotic patients . A powerful mechanism is the specific bind of HCV to platelet membrane CD81 receptor; therefore, production of autoantibody against this complex results in platelets phagocytosis .…”

Section: Discussionmentioning

confidence: 99%

“…30 Several studies reported that CHC infection is strongly correlated with thrombocytopenia, indicating that 64-76% of CHC infections, fibrosis, and cirrhosis showed manifestations of thrombocytopenia, compared with 6% of non-cirrhotic patients. 31,32 A powerful mechanism is the specific bind of HCV to platelet membrane CD81 receptor; therefore, production of autoantibody against this complex results in platelets phagocytosis. 33 It might also occur in OCI.…”

Section: T He Current Study Comprehensively Evaluated the Prevalence mentioning

confidence: 99%

See 1 more Smart Citation

Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection?

Ayadi

Nafari

Sakhaee

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

Aim The presence of occult hepatitis C virus (HCV) infection (OCI) is still controversial, however, this infection cannot be ignored. Therefore, the current study aimed at assessing the OCI frequency in patients on chronic hemodialysis (CHD) and also evaluating the association between OCI incidence with clinical parameters and interferon lambda 3/4 (IFNL3/4) gene polymorphisms. Methods A total of 515 patients on CHD and HCV negative markers were selected. Plus‐ and minus‐stranded HCV‐RNA was tested in peripheral blood mononuclear cell samples by reverse transcription–polymerase chain reaction and then genotyped using the restriction fragment length polymorphism method. Results The frequency of OCI was 11.3% in patients on CHD. Among 58 patients with OCI, 25.8%, 62.1%, and 12.1% were infected with HCV‐1a, HCV‐1b, and HCV‐3a, respectively. The mean alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels were 31.9 ± 24.8, 32.3 ± 19.1, and 171.6 ± 88.9, respectively. None of the patients with OCI had a history of liver disease. Multivariate logistic regression analysis indicated that cholesterol, triglyceride, low‐density lipoprotein, 25‐hydroxyvitamin D, platelets, duration of hemodialysis, HCV subtypes, IFNL3 rs12979860 TT, IFNL3 rs8099917 GG, IFNL3 rs12980275 GG, and IFNL4 ss469415590 ΔG/ΔG genotypes were associated with OCI. Conclusion There was a moderate prevalence of OCI in Iranian patients on CHD. The current study findings indicated that this infection was associated with clinical parameters and unfavorable genotypes of IFNL3 single nucleotide polymorphisms and IFNL4 ss469415590. Further studies are required to determine the correlation between OCI incidence with clinical parameters and host genetic factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: T He Current Study Comprehensively Evaluated the Prevalence mentioning

confidence: 99%

Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection?

Ayadi

Nafari

Sakhaee

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Findings of this study are higher than our study. In another study by Bano et al 14 13 found thrombocytopenia in 57.3% male patients. In same study most of the cases belonged to 5 th decade.…”

Section: Discussionmentioning

confidence: 86%

A Study of thrombocytopenia in cases of Hepatitis C infection presenting at tertiary care hospital

Raziq¹,

Hussain²,

Munir³

et al. 2021

PJMHS

View full text Add to dashboard Cite

Aim: To determine the frequency of thrombocytopenia in hepatitis c patients presenting at tertiary care hospital. Methods: This cross sectional study was conducted at Department of Physiology in collaboration with Department of Medicine, Bahawal Victoria Hospital, Bahawalpur from March 2020 to September 2020 over the period of 6 months. Total 150 of hepatitis C, either male or female having age 20-60 years were included. Thrombocytopenia was assessed in selected patients. Results: In this study mean age of the patients was 44±12.38 years. Out of 150 patients of hepatitis C, thrombocytopenia was present in 48(32%) patients. In age group 20-40 years, thrombocytopenia was found in 14(26.92%) patients while in age group 41-60 years, thrombocytopenia was seen in 34(34.69%) patients. No statistically significant association of thrombocytopenia with age group was detected with p value 0.332. Male patients were 93(62%) and female patients were 57(38%). Thrombocytopenia was found in 30(32.26%) male patients and in 18(31.58%) female patients. Association of thrombocytopenia with gender was not statistically significant with p value 0.931. Conclusion: Results of present study revealed that higher proportion of hepatitis C patients found with thrombocytopenia. Most of the patients belonged to 4th and 5th decade. Higher number of male patients were victim of hepatitis C infection as compared to female patients. Most of the patients were obese. Higher number of patients were normotensive and non-diabetics. Keywords: Hepatitis C, thrombocytopenia, cirrhosis, hepatocellular carcinoma

show abstract

“…We have read, with great interest, the study conducted by Bano et al (1) in your journal. The aim of their study was to investigate the prevalence of thrombocytopenia in HCV patients without cirrhosis and splenomegaly.…”

Section: Dear Editormentioning

confidence: 99%

Thrombocytopenia in Confirmed HCV Cases

2016

View full text Add to dashboard Cite

We have read, with great interest, the study conducted by Bano et al. (1) in your journal. The aim of their study was to investigate the prevalence of thrombocytopenia in HCV patients without cirrhosis and splenomegaly. They recruited 30 patients for the study, and found the prevalence of thrombocytopenia to be 43.3%. Moreover, they concluded that thrombocytopenia was of moderate frequency in HCV participants. Undoubtedly, HCV is a public health problem worldwide, especially in developing countries (2, 3). The classical treatment of HCV is challenging and fraught with poor tolerability and side effects. A major breakthrough occurred in managing HCV with new direct acting antiviral regimens with less side effects and more tolerability. However, the use of such new regimens is restricted due to their high price; therefore, classification of the patients is necessary (4). Here comes the importance of thrombocytopenia, as it can be considered a contraindication for the classical regimen (5, 6). Any patient with thrombocytopenia might be eligible for the new expensive medications. Hence, it might be important for the public health planners to estimate the prevalence of thrombocytopenia in HCV. Furthermore, thrombocytopenia in chronic HCV patients is associated with bleeding tendency, and it is a poor prognostic factor. However, it is important to clarify that HCV-antibody positivity does not indicate current infection, but shows an exposure to the virus. To a large extent, the diagnosis of HCV depends on the PCR positivity. Thus, any study targeting HCV patients should include patients with confirmed PCR results. Moreover, a larger sample size is needed for prevalence study. Therefore, the recruitment of a larger sample with a confirmed current HCV infection is highly recommended.

show abstract

Thrombocytopenia as a Clinical Manifestation of Hepatitis C Among Patients With a Positive Anti-HCV Test

Cited by 10 publications

References 17 publications

Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection?

Host genetic factors and clinical parameters influencing the occult hepatitis C virus infection in patients on chronic hemodialysis: Is it still a controversial infection?

A Study of thrombocytopenia in cases of Hepatitis C infection presenting at tertiary care hospital

Thrombocytopenia in Confirmed HCV Cases

Contact Info

Product

Resources

About